The fall in Infosys' US-listed shares came despite the company revising its revenue growth guidance higher for the third ...

Infosys raised its revenue forecast for the fourth straight quarter, projecting 4.5-5% growth for the 2024-25 fiscal year.

Brian DeSchuytner, the Senior Vice President, Chief Operating Officer, and Chief Financial Officer of Mersana Therapeutics, Inc. (NASDAQ:MRSN), recently reported a transaction involving the company's ...